Fluomizin contains excipients that do not completely dissolve. Remnants of the pill can sometimes be found on underwear. This does not affect the effectiveness of Fluomizin. Sometimes in cases where there is dryness of the vagina, there is a possibility that the vaginal tablet does not dissolve and is released from the vagina whole. As a result, this treatment is not effective. To prevent this, before inserting the tablet into a dry vagina, you can moisten the tablet with a small amount of water. Patients should use sanitary pads or daily pads.
active substance: dequalinium chloride;
1 vaginal tablet contains 10 mg of dequalinium chloride;
excipients: lactose monohydrate; microcrystalline cellulose; magnesium stearate.
Fluomizin Dosage form.
Main physical and chemical properties: white or almost white oval biconvex tablets.
Antimicrobial and antiseptic agents used in gynecology.
ATX code G01A C05.
Fluomizin Pharmacological properties.
Fluomizine contains dequalinium chloride – a Quaternary ammonium compound with a broad antimicrobial spectrum of action against various gram-positive and gram-negative bacteria, fungi and simple single-celled organisms (Trichomonas vaginalis).
Mechanism of action
Dequalinium chloride is a surfactant. The main mechanism of action of dequalinium chloride is to increase the permeability of the bacterial cell and the subsequent loss of enzyme activity, which leads to cell death.
Dequalinium chloride has a rapid bactericidal and fungicidal action.
Dequalinium chloride in vaginal tablets acts locally in the vagina. A noticeable reduction in discharge and inflammation usually occurs after 24-72 hours.
Pharmacokinetic / pharmacodynamic relationship
No limiting effect of pharmacokinetics / pharmacodynamics on the efficacy of Fluomizine has been established. As the bactericidal action of dequalinium chloride occurs within 30-60 minutes, the maximum local concentration during the first hour after application is crucial for effectiveness.
Mechanisms of resistance
The mechanisms leading to the emergence of primary resistance of pathogenic microorganisms have not been identified. The development of acquired resistance of microorganisms to dequalinium chloride has not been reported.
Limit values are not regulated and a relationship between minimum inhibitory concentrations (MICs) and clinical efficacy has not been established.
Thus, the information on the susceptibility of microorganisms below is based on the concentrations achieved in the vagina (see section “Pharmacokinetics”) and the relevant data on the MIC of pathogenic microorganisms.
· Vaginal infections of bacterial and fungal origin.
· Bacterial vaginosis.
· Hypersensitivity to the active substance or to any of the excipients.
· Ulcers of the epithelium of the vagina and vaginal part of the cervix.
· Do not use in young girls who have not had their first period and who have not reached puberty.